Irvine, CA – According to filings with the U.S. Securities and Exchange Commission, JenaValve Technology is raising $100,400,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Victoria Brendel played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About JenaValve Technology
JenaValve Technology, Inc., with locations in Irvine, Calif., Leeds, U.K. and Munich, Germany, develops and manufactures transcatheter aortic valve replacement (TAVR) systems to treat patients suffering from aortic valve disease. The Company is in clinical development of its next-generation transfemoral TAVR system in both the U.S. and CE mark countries for treating patients with aortic stenosis and/or aortic regurgitation. In addition to Bain Capital Life Sciences, JenaValve is backed by European and Asian investors, including Andera Partners (formerly Edmond de Rothschild Investment Partners), Gimv (Euronext: GIMB), Legend Capital, NeoMed Management, RMM, Valiance Life Sciences and VI Partners.

To learn more about JenaValve Technology, visit http://www.jenavalve.com/

Contact:
Victoria Brendel, Chief Executive Officer
949-767-2110
https://www.linkedin.com/in/victoria-carr-brendel-564431/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved